Transcriptional-translational conflict is a barrier to cellular transformation and cancer progression

Cancer Cell. 2023 May 8;41(5):853-870.e13. doi: 10.1016/j.ccell.2023.03.021. Epub 2023 Apr 20.

Abstract

We uncover a tumor-suppressive process in urothelium called transcriptional-translational conflict caused by deregulation of the central chromatin remodeling component ARID1A. Loss of Arid1a triggers an increase in a nexus of pro-proliferation transcripts, but a simultaneous inhibition of the eukaryotic elongation factor 2 (eEF2), which results in tumor suppression. Resolution of this conflict through enhancing translation elongation speed enables the efficient and precise synthesis of a network of poised mRNAs resulting in uncontrolled proliferation, clonogenic growth, and bladder cancer progression. We observe a similar phenomenon in patients with ARID1A-low tumors, which also exhibit increased translation elongation activity through eEF2. These findings have important clinical implications because ARID1A-deficient, but not ARID1A-proficient, tumors are sensitive to pharmacologic inhibition of protein synthesis. These discoveries reveal an oncogenic stress created by transcriptional-translational conflict and provide a unified gene expression model that unveils the importance of the crosstalk between transcription and translation in promoting cancer.

Keywords: ARID1A; MAP kinase; RASGRP1; SWI/SNF; bladder cancer; eEF2; eEF2K; homoharringtonine; transcription; translation elongation.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Chromatin*
  • Humans
  • Urinary Bladder Neoplasms* / genetics

Substances

  • Chromatin